Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib plus chemotherapy in COX-dependent recurrent NSCLC
NCT00520845Phase 2Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of celecoxib oral solution in non-small cell lung cancer (NSCLC), sponsored by Vanderbilt-Ingram Cancer Center. Started Oct 2007; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00520845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520845.